Skip to main content

Table 1 Disease and patient characteristics of thyroid specimens used in this study

From: A novel microfluidic device capable of maintaining functional thyroid carcinoma specimens ex vivo provides a new drug screening platform

No

Tumour stage

Patient age range (years)

Tissue received

1

T2NXMX

40–50

M

2

T4aN1bMX

40–50

M

3

T3aNXMX

40–50

M

4

BG

50–60

B

5

T2NXMX

50–60

M,B

6

T3N1bMX

20–30

M

7

T4N0M0

80–90

M

8

T1aNXMX

60–70

M

9

BG

60–70

B

10

T2N1BMX

30–40

M,B

11

T3N1aMX

50–60

M

12

BG

30–40

B

13

BG

50–60

B

14

T4N0M1

50–60

M

15

T1aN1bMX

40–50

M

16

T1bNXMX

40–50

M,B

17

T3aNXMX

10–20

M

18

T3bN1aMX

40–50

M,B

19

T1NXMX

60–70

M,B

20

T1aNXMX

10–20

M

21

T3AN1bMX

30–40

M,B

22

T3aN1bM0

20–30

M

23

T1aNXMX

40–50

M,B

24

T3N1bM0

30–40

M,B

25

T2NXMX

70–80

M,B

26

T3aNXMX

60–70

M

27

T4aN1bMX

70–80

M,B

  1. BG Benign goitre, M Malignant tissue, B Benign tissue